AU2010220397A1 - BANK1 related SNPS and SLE and/or MS susceptibility - Google Patents
BANK1 related SNPS and SLE and/or MS susceptibility Download PDFInfo
- Publication number
- AU2010220397A1 AU2010220397A1 AU2010220397A AU2010220397A AU2010220397A1 AU 2010220397 A1 AU2010220397 A1 AU 2010220397A1 AU 2010220397 A AU2010220397 A AU 2010220397A AU 2010220397 A AU2010220397 A AU 2010220397A AU 2010220397 A1 AU2010220397 A1 AU 2010220397A1
- Authority
- AU
- Australia
- Prior art keywords
- bank1
- snps
- individual
- rsl
- sle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100021568 B-cell scaffold protein with ankyrin repeats Human genes 0.000 title claims abstract description 67
- 101000971155 Homo sapiens B-cell scaffold protein with ankyrin repeats Proteins 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 claims abstract description 42
- 238000003205 genotyping method Methods 0.000 claims abstract description 13
- 230000002068 genetic effect Effects 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 15
- 108700028369 Alleles Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 2
- 101000975421 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 2 Proteins 0.000 claims 4
- 102100024037 Inositol 1,4,5-trisphosphate receptor type 2 Human genes 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 1
- 101710135413 B-cell scaffold protein with ankyrin repeats Proteins 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 37
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 29
- 230000003993 interaction Effects 0.000 description 27
- 230000002922 epistatic effect Effects 0.000 description 20
- 201000006417 multiple sclerosis Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000037361 pathway Effects 0.000 description 10
- 238000010197 meta-analysis Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 description 6
- 101100042371 Caenorhabditis elegans set-3 gene Proteins 0.000 description 6
- 102100029768 Histone-lysine N-methyltransferase SETD1A Human genes 0.000 description 6
- 101000865038 Homo sapiens Histone-lysine N-methyltransferase SETD1A Proteins 0.000 description 6
- 101150117538 Set2 gene Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 102200015609 rs10516487 Human genes 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 3
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 3
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 description 3
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 101100381461 Homo sapiens BANK1 gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100126626 Drosophila melanogaster Itpr gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 description 1
- 101000597273 Homo sapiens PHD finger protein 11 Proteins 0.000 description 1
- 101000935642 Homo sapiens Phosphoinositide 3-kinase adapter protein 1 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100035126 PHD finger protein 11 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15697009P | 2009-03-03 | 2009-03-03 | |
| EP09154190.4 | 2009-03-03 | ||
| EP09154190 | 2009-03-03 | ||
| US61/156,970 | 2009-03-03 | ||
| PCT/EP2010/052554 WO2010100113A1 (fr) | 2009-03-03 | 2010-03-01 | Polymorphismes nucléotidiques associés au gène bank1 et sensibilité au lupus érythémateux disséminé et/ou à la sclérose en plaques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010220397A1 true AU2010220397A1 (en) | 2011-07-28 |
Family
ID=40549875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010220397A Abandoned AU2010220397A1 (en) | 2009-03-03 | 2010-03-01 | BANK1 related SNPS and SLE and/or MS susceptibility |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110319288A1 (fr) |
| EP (1) | EP2403959A1 (fr) |
| JP (1) | JP2012519009A (fr) |
| AU (1) | AU2010220397A1 (fr) |
| CA (1) | CA2749869A1 (fr) |
| IL (1) | IL214580A0 (fr) |
| WO (1) | WO2010100113A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009296393A1 (en) * | 2008-09-26 | 2010-04-01 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring lupus |
| CN105518146B (zh) | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
| EP2984180A4 (fr) * | 2013-04-11 | 2016-12-14 | Broad Inst Inc | Sle et marqueurs de risque associés à une maladie liée à sle et leurs utilisations |
| CN115537396A (zh) | 2015-03-27 | 2022-12-30 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
| WO2018195129A1 (fr) | 2017-04-17 | 2018-10-25 | University Of Maryland, College Park | Cultures de cellules embryonnaires et leurs procédés d'utilisation |
| WO2021127589A1 (fr) * | 2019-12-18 | 2021-06-24 | The Children's Hospital Of Philadelphia | Nouvelles cibles pharmacopotentielles pour le traitement de maladies inflammatoires telles que le lupus érythémateux disséminé (sle) et méthodes de diagnostic et de traitement l'utilisant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE518007T1 (de) * | 2005-10-21 | 2011-08-15 | Genenews Inc | Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen |
| WO2007115207A2 (fr) * | 2006-03-31 | 2007-10-11 | Regents Of The University Of Minnesota | Haplotypes irf-5 dans le lupus érythémateux systèmique |
| EP2158335A2 (fr) * | 2007-05-21 | 2010-03-03 | Genetech, Inc. | Procédés et compositions pour l'identification et le traitement du lupus |
-
2010
- 2010-03-01 CA CA2749869A patent/CA2749869A1/fr not_active Abandoned
- 2010-03-01 AU AU2010220397A patent/AU2010220397A1/en not_active Abandoned
- 2010-03-01 US US13/147,377 patent/US20110319288A1/en not_active Abandoned
- 2010-03-01 WO PCT/EP2010/052554 patent/WO2010100113A1/fr active Application Filing
- 2010-03-01 JP JP2011552407A patent/JP2012519009A/ja active Pending
- 2010-03-01 EP EP10705608A patent/EP2403959A1/fr not_active Withdrawn
-
2011
- 2011-08-10 IL IL214580A patent/IL214580A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL214580A0 (en) | 2011-09-27 |
| WO2010100113A1 (fr) | 2010-09-10 |
| JP2012519009A (ja) | 2012-08-23 |
| US20110319288A1 (en) | 2011-12-29 |
| CA2749869A1 (fr) | 2010-09-10 |
| EP2403959A1 (fr) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Turlure et al. | A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo | |
| DK2751284T3 (en) | PROCEDURE FOR DIAGNOSTICING A NEURODEGENERATIVE DISEASE | |
| Wang et al. | PRP16, a DEAH-box RNA helicase, is recruited to the spliceosome primarily via its nonconserved N-terminal domain | |
| Královičová et al. | PUF60-activated exons uncover altered 3′ splice-site selection by germline missense mutations in a single RRM | |
| Sagvekar et al. | Pathomechanisms of polycystic ovary syndrome: multidimensional approaches | |
| US20050208486A1 (en) | Brca-1 regulators and methods of use | |
| AU2010220397A1 (en) | BANK1 related SNPS and SLE and/or MS susceptibility | |
| US11441190B2 (en) | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced SMARCA4 gene expression or protein function | |
| US20080038365A1 (en) | TRPC6 involved in glomerulonephritis | |
| JP2005110602A (ja) | アトピー性皮膚炎の疾患マーカー及びその利用 | |
| JP2009539960A (ja) | 加齢黄斑変性に対する保護および処置 | |
| Ianzano et al. | Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product | |
| JP7177439B2 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| Jiang et al. | Post-GWAS functional analysis identifies CUX1 as a regulator of p16INK4a and cellular senescence | |
| Easton et al. | A rare missense mutation in GJB3 (Cx31G45E) is associated with a unique cellular phenotype resulting in necrotic cell death | |
| WO2014018375A1 (fr) | Cyp8b1 et ses utilisations dans des méthodes thérapeutiques et diagnostiques | |
| Zhang et al. | Mutation analysis of autosomal dominant polycystic kidney disease genes in Han Chinese | |
| Damjanovic et al. | Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma | |
| JP7150018B2 (ja) | 新規なｃｉｐ２ａバリアント及びその使用 | |
| Manos et al. | Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-γ regulated gene negatively associated with prostate tumor invasion | |
| Skinningsrud et al. | X-linked congenital adrenal hypoplasia with hypogonadotropic hypogonadism caused by an inversion disrupting a conserved noncoding element upstream of the NR0B1 (DAX1) gene | |
| Arseneau et al. | Multiple isoforms of PAX5 are expressed in both lymphomas and normal B‐cells | |
| Tiscia et al. | Functional characterization of annexin A5 gene promoter allelic variants | |
| Norppa et al. | Distinct functions for the paralogous RBM41 and U11/U12-65K proteins in the minor spliceosome | |
| Krahn et al. | Transcriptional explorations of CAPN3 identify novel splicing mutations, a large‐sized genomic deletion and evidence for messenger RNA decay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ BANK1 RELATED SNPS AND SLE AND/ OR MS SUSCEPTIBILITY |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |